美国银行全球研究已开始对生物制药公司Parabilis Medicines进行覆盖分析，并首次给予其股票“买入”评级。该机构为Parabilis Medicines设定了45.00美元的目标股价，显示出对其未来增长潜力的积极预期。
美国银行全球研究已开始对生物制药公司Parabilis Medicines进行覆盖分析，并首次给予其股票“买入”评级。该机构为Parabilis Medicines设定了45.00美元的目标股价，显示出对其未来增长潜力的积极预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.